November 16, 2026
Source: drugdu
40

On November 14, Conba announced that Adneuris Therapeutics, which holds overseas rights to cebranopadol, had submitted a New Drug Application to the US FDA for moderate to severe acute pain in adults. Cebranopadol is an investigational oral analgesic that acts on both NOP and mu-opioid receptors.
The filing draws on two pivotal Phase III trials, ALLEVIATE-1 and ALLEVIATE-2, which studied acute pain after abdominoplasty and bunionectomy, respectively. Conba said both trials met their primary efficacy endpoints, with lower pain intensity and less use of rescue analgesics than placebo. Neither trial reported serious adverse events related to the study drug. The filing also includes data from a human abuse potential study.
On July 3, 2026, two Conba subsidiaries signed an agreement with Adneuris for development and commercialization rights in Greater China, with an upfront payment, milestone payments and royalties. Adneuris expects the FDA to communicate its filing decision within approximately 60 days of submission. The outcome and timing of any approval remain subject to review.
Source: http://finance.eastmoney.com/a/202611163931611874.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.